Does Aetna Pay for GLP-1 Medications? (2026)
What Aetna pays for, what it asks of you first, what it costs when the answer is yes, and where to go when it is no.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Where Each Medication Stands[8]
| Medication | What Aetna does |
|---|---|
| Wegovy (semaglutide) | Aetna covers Wegovy on Non-Medicare commercial plans under bulletin 4774-C UDR 08-2023 v2 (effective 05/01/2024). Adult initial criteria: patient must be >=18, have BMI >=30 (or BMI >=27 with one weight-related comorbidity), and have participated in a comprehensive weight-management program for at least 6 months prior to drug therapy. Initial approval is 7 months; continuation/reauthorization is 12 months and requires documented loss of at least 5% of baseline body weight (or maintained 5% loss). Pediatric (12-17): BMI in the 95th percentile or greater + 6-month program. Wegovy also has a separate cardiovascular risk-reduction pathway in 4774-C for patients with established CVD on guideline-directed management and therapy who do NOT have type 2 diabetes. CVS Caremark (Aetna's PBM, both CVS Health subsidiaries) designated Wegovy the PREFERRED commercial GLP-1 in July 2025 — most Aetna commercial books now step toward Wegovy. Quantity limits: 0.25-1 mg = 2 mL per 21 days; 1.7-2.4 mg = 3 mL per 21 days. |
| Ozempic (semaglutide) | Aetna covers Ozempic for type 2 diabetes per bulletin 2439-C UDR 05-2024 (last reviewed 10/27/2024). Initial PA requires the patient is NOT on stable GLP-1 maintenance >=3 months AND meets one of: (1) inadequate response, intolerance, or contraindication to metformin; (2) requires combination therapy AND has A1C >=7.5%; (3) eGFR <30 mL/min/1.73m^2; or (4) established cardiovascular disease. Continuation requires stable maintenance >=3 months AND demonstrated A1C reduction since starting GLP-1 therapy. Aetna Medicare Part D plans cover Ozempic for type 2 diabetes (NOT for off-label weight loss). Quantity limits vary by strength: 2 mg/1.5 mL = 1 pen per 21 days; 4 mg/3 mL and 8 mg/3 mL = 1 pen per 21 days. Verbatim MACE language in the bulletin: 'reduce the risk of major adverse cardiovascular events…in adults with type 2 diabetes mellitus and established cardiovascular disease.' |
| Zepbound (tirzepatide) | Aetna covers Zepbound on Non-Medicare commercial plans per bulletin 6947-C P04-2025 (effective 07/01/2025), which supersedes the older 6192-C. Adult criteria: BMI >=30 OR BMI >=27 with one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia), plus participation in a comprehensive weight-management program for at least 6 months prior to drug therapy. Continuation requires documented >=5% baseline body-weight loss. Separate OSA pathway covers moderate-to-severe OSA in adults with obesity (AHI >=15 events/hour). CRITICAL CAVEAT: a separate Zepbound Exception bulletin 6981-A P04-2025 applies on plan-formulary codes ACCF/ACF/ACFC/SCCF/SF/SFC/VF/VFC where Wegovy is the preferred step. CVS Caremark removed Zepbound from MOST commercial formularies effective July 2025 in favor of Wegovy as the single preferred GLP-1, so many Aetna commercial members now see Zepbound denials they did not see in 2024. Aetna Medicare Part D does NOT cover Zepbound for weight loss (statutory exclusion); may cover for OSA indication. Beginning 07/01/2026, only the Zepbound KwikPen formulation (NOT vials/single-dose pens) is available to MA-PD members via the CMS Medicare GLP-1 Bridge. Quantity limits all strengths: 2 mL (1 package of 4 pens) per 21 days; 6 mL (3 packages of 4 pens) per 63 days. |
| Mounjaro (tirzepatide) | Aetna covers Mounjaro for type 2 diabetes per bulletin 5468-C UDR 05-2024 (last reviewed 10/27/2024). Initial PA verbatim: 'The patient has NOT been receiving a stable maintenance dose of the requested drug for at least 3 months and ONE of the following criteria are met' — either metformin inadequacy/intolerance/contraindication, OR combination therapy AND A1C >=7.5%. Continuation requires stable maintenance >=3 months AND demonstrated A1C reduction (approval period 36 months). Aetna Medicare Part D plans cover Mounjaro for type 2 diabetes (NOT for off-label weight loss). Quantity limits: 4 single-dose pens or vials (2 mL) per 21 days OR 12 single-dose pens or vials (6 mL) per 63 days. |
| Foundayo (orforglipron) | Aetna had not published a primary-source PA bulletin for Foundayo (orforglipron) on aetna.com as of 2026-05-09 — FDA approval was 04/01/2026 and Aetna's bulletin update cadence has not yet incorporated it. Coverage is currently determined at the plan/employer level. Where covered, expect criteria to mirror the Wegovy 4774-C framework (BMI >=30 or >=27 with comorbidity, 6-month comprehensive weight-management program, 5% continuation). For Aetna Medicare Part D members, all Foundayo formulations are included in the CMS Medicare GLP-1 Bridge at $50/month flat copay beginning 07/01/2026 through 12/31/2027 for members with BMI >=27 plus heart disease or prediabetes. Re-verify Aetna primary source quarterly. |
| Saxenda (liraglutide) | Aetna covers Saxenda (liraglutide for chronic weight management) per bulletin 1227-C P08-2024_R (12/19/2024). Adult criteria: BMI >=30, or BMI >=27 with at least one weight-related comorbid condition (verbatim list: hypertension, type 2 diabetes mellitus, or dyslipidemia), AND participation in a comprehensive weight-management program (behavioral modification, reduced-calorie diet, AND increased physical activity with continuing follow-up) for at least 6 months prior to drug therapy. Pediatric (12-17): BMI corresponding to >=30 kg/m^2 for adults by international cut-offs (Cole Criteria) + 6-month program. CRITICAL DIFFERENCE FROM WEGOVY/ZEPBOUND: Saxenda continuation requires loss of >=4% of baseline body weight (NOT 5%), or maintained 4% loss. Pediatric continuation requires >=1% reduction in BMI from baseline. Saxenda is NOT included in the CMS Medicare GLP-1 Bridge effective 07/01/2026. Quantity limits: 15 mL (1 package of five 3 mL pens) per 25 days; 45 mL (3 packages) per 75 days. |
| Copay when it is covered | $25-$80 / month |
After a Denial from Aetna
A refusal on Wegovy or Zepbound is not the end of the road. Licensed 503A pharmacies[7] dispense compounded semaglutide and tirzepatide at $149-$299 a month, well under what the brand costs. Two other things are worth knowing. With a prescription, a brand-name GLP-1 is generally an eligible HSA or FSA medical expense[5], and a good number of plan administrators will accept a compounded one on a Letter of Medical Necessity. The services listed below ship to all 50 states and usually write inside the week.
Large employers often self-fund, which puts the plan under ERISA rather than state insurance law and leaves the employer free to decide whether anti-obesity medication is covered at all[6]. If yours self-funds, the answer sits in the Summary Plan Description, in the GLP-1 language specifically.
Lodge the formal appeal with Aetna first. Ask your prescriber for a Letter of Medical Necessity that documents your BMI, any comorbidities, and the weight-loss attempts that did not work. Appeals carrying one overturn a real share of denials.
Every Aetna GLP-1 bulletin is reproduced word for word in our guide: the CVS Caremark formulary swap of July 2025 that made Wegovy preferred, which drives most 2026 denials; the metformin-first step rule on Mounjaro and Ozempic; the Zepbound 6981-A exception, carried on plan codes ACCF, ACF and ACFC, plus SCCF, SF, SFC, VF and VFC; the Wegovy reauth window of 7 months; the Saxenda continuation threshold set at 4% (NOT 5%); the CMS Medicare GLP-1 Bridge, which starts 07/01/2026; and how Foundayo is handled. Read it in the Aetna GLP-1 Prior Authorization Guide.
Cash-pay GLP-1 services if Aetna says no
Cash-pay compounded semaglutide and tirzepatide are not hard to find, and after a denial the monthly cost often lands under what a covered copay would have been. Our highest-ranked picks come first, then the longer list.
Our picks
Compare the top providers at a glance
Every row carries a logo, our editorial rating, price, the medications prescribed, and where the seller ships. Scan down a column and the list shortens fast.
- ★ Editor's Pick
semaglutide at $99/month, 48% under the register median
From /mo$99Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatide - Best Budget
semaglutide at $99/month, 48% under the register median
From /mo$99Coverage50 statesMedicationsSemaglutideTirzepatide - Nationwide Coverage
tirzepatide at $169/month, 37% under the register median
From /mo$99Coverage50 statesMedicationsSemaglutideTirzepatide moving between compounded and brand without changing seller
From /mo$129Flat at every doseCoverage50 statesMedicationsSemaglutideTirzepatidesemaglutide at $99/month, 48% under the register median
From /mo$99Coverage49 statesMedicationsSemaglutideTirzepatide
| Provider | Rating | From /mo | Medications | Coverage | |
|---|---|---|---|---|---|
★ Editor's Pick semaglutide at $99/month, 48% under the register median | $99 Flat pricing | SemaglutideTirzepatide | 50 states | Visit → | |
Best Budget semaglutide at $99/month, 48% under the register median | $99 | SemaglutideTirzepatide | 50 states | Visit → | |
Nationwide Coverage tirzepatide at $169/month, 37% under the register median | $99 | SemaglutideTirzepatide | 50 states | Visit → | |
 moving between compounded and brand without changing seller | $129 Flat pricing | SemaglutideTirzepatide | 50 states | Visit → | |
 semaglutide at $99/month, 48% under the register median | $99 | SemaglutideTirzepatide | 49 states | Visit → |
The longer list of compounded options
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Kairos Aesthetic and Longevity Medicine
Best for: a published state list — 1 of 50 — when most of the register publishes none
Editorial score · methodology
Get StartedRead full Kairos Aesthetic and Longevity Medicine review →Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Trimrose
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Prior authorization (PA) · Insurance and regulatory
- Step therapy · Insurance and regulatory
- Off-label use · Insurance and regulatory
- Compounded GLP-1 · Pharmacy and drug forms
Aetna coverage changes
We will email you if Aetna changes its GLP-1 rules.
Sources & methodology — as of August 2026
- 1.KFF — Employer Health Benefits Annual Survey— Kaiser Family Foundation.
- 2.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 3.CMS — Medicare Part D Prescription Drug Coverage Program— Centers for Medicare & Medicaid Services.
- 4.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
- 6.U.S. Department of Labor — ERISA and Employer Health Plans— U.S. Department of Labor, Employee Benefits Security Administration.
- 7.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 8.GLP Watchdog insurer coverage index (manually curated formulary data)— GLP Watchdog.